Company / Depreciation & Amortization
NewAmsterdam Pharma Co N.V. Depreciation & Amortization History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$220.0K
FY2025
5-year range
$5.0K / $220.0K
FY2021-FY2025
Trend
+94.7%
vs FY2024
Sector context
#173 of 192
Health Care
What the data says
Among 192 Health Care companies, NewAmsterdam Pharma Co N.V. is in the top 10% for depreciation & amortization. Depreciation & Amortization has increased for 4 consecutive years, from $5,000 in FY2021 to $220,000 in FY2025.
Based on SEC 10-K filings.
$220,000 in FY2025 with a 3-year CAGR of +190.2%.
Increased from $49,000 to $220,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +190.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.9% below sector average
Key checks
Key Insights
- NewAmsterdam Pharma Co N.V.'s depreciation & amortization has grown for 4 consecutive years.
- 3-year CAGR of +190.2%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 94.7% year-over-year.
- Ranks #173 out of 192 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $220.0K | +94.7% |
| FY2024 | $113.0K | +130.6% |
| FY2023 | $49.0K | +444.4% |
| FY2022 | $9.0K | +80.0% |
| FY2021 | $5.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026